<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467919</url>
  </required_header>
  <id_info>
    <org_study_id>41688</org_study_id>
    <nct_id>NCT03467919</nct_id>
  </id_info>
  <brief_title>The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis</brief_title>
  <official_title>The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-surgical trial comparing the clinical and functional outcomes of patients with
      osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue
      versus conventional therapy of intra-articular injection of corticosteroid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized controlled trial to compare outcomes between intra-articular
      injection of Micro Fragmented Adipose Tissue and intra-articular injection of corticosteroid
      in patients with mild to moderate osteoarthritis of the knee. Micro Fragmented Adipose Tissue
      will be harvested at the subcutaneous tissue by lipoaspiration. Once fat tissue is obtained,
      it will be processed with minimal manipulation in the clinic room.

      To be considered for participation in this study, patients must have radiographic evidence of
      mild to moderate osteoarthritis of medial and/or lateral weight-bearing compartments
      (Kellgren-Lawrence Grade 2 or 3). In addition, patients must meet several inclusion/exclusion
      criteria to be randomized and included in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score</measure>
    <time_frame>24 months</time_frame>
    <description>Patient reported outcome measure that reports a normalized score (100 indicating no symptoms and 0 indicating extreme symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lysholm score</measure>
    <time_frame>24 months</time_frame>
    <description>Patient reported activity outcome measure on a scale of 0-100 (100 is best activity score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veterans RAND 12 (VR-12) score</measure>
    <time_frame>24 months</time_frame>
    <description>Patient reported quality of life outcome measure on a scale of 0-50 with 50 being healthy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MRI Cartilage Scan</measure>
    <time_frame>12 months</time_frame>
    <description>Cartilage thickness on MRI using T2-weighted cartilage mapping</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Knee Pain</condition>
  <arm_group>
    <arm_group_label>MFAT(Micro Fragmented Adipose Tissue)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-articular injection of corticosteroid (Triamcinolone 40mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Micro Fragmented Adipose Tissue</intervention_name>
    <description>Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection</description>
    <arm_group_label>MFAT(Micro Fragmented Adipose Tissue)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Corticosteroid injection</intervention_name>
    <description>Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.</description>
    <arm_group_label>Conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 35 and 75 years-old

          -  Diagnosis of pre-existing osteoarthritis of the joint by Kellgren-Lawrence Grade 2 or
             3.

          -  Working understanding of the English language and able to fully understand the
             procedure

          -  Capable of providing informed consent

          -  Able to complete online, in-person or phone surveys for the purposes of follow-up

          -  Capable of understanding pre- and post-procedure care instructions

          -  Ambulatory at baseline

          -  Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks
             of physical therapy and trial of anti-inflammatory medications if not contraindicated,
             with or without concomitant bracing and/or injections.

        Exclusion Criteria:

          -  Age &lt; 35 or &gt; 75 years old

          -  Radiographs demonstrating either no, little or severe osteoarthritis
             (Kellgren-Lawrence Grade 0, 1 )

          -  Prior total or partial joint replacement surgery or a surgery involving cartilage
             regeneration (microfracture, ACI, etc)

          -  Previous cortisone and/or Hyaluronic acid intra-articular injection within the last 3
             months

          -  Co-morbidity with rheumatologic condition, inflammatory arthritis

          -  Currently undergoing immunomodulatory therapy

          -  Uncontrolled endocrine disorder

          -  BMI &gt;35

          -  Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and/or
             hepatitis C (HCV), infection and poorly controlled diabetes (HgA1C &gt;7.0)

          -  Pregnancy or planned pregnancy

          -  previous stem cell injection into treatment joint

          -  Patient scheduled to undergo any concomitant surgical procedures.

          -  Coagulopathy or anticoagulant treatment

          -  Chronic pain involving multiple body parts or opioid medication management
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Y Roh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Dragoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seth Sherman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ma Agnes Ith, MD</last_name>
    <phone>(650) 721-7600</phone>
    <email>mith@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Y Roh, MD</last_name>
      <phone>650-721-7600</phone>
      <email>mith@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Eugene Y Roh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>eyroh</investigator_full_name>
    <investigator_title>Director, Sports Ultrasound Medicine, Orthobiologics</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>stem cell</keyword>
  <keyword>knee pain</keyword>
  <keyword>adipose derived stem cell</keyword>
  <keyword>injection</keyword>
  <keyword>MFAT</keyword>
  <keyword>Micro Fragmented Adipose Tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

